anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an aroma therapy, a health method for rubbing in skin, or a beauty method, for promoting the volatilization of a perfume, or an aroma produced from an aromatic plant in aroma therapy.  &lt;P&gt;SOLUTION: The volatilization of an aromatic oil is promoted to exhibit an effective aroma therapy effect for an ingredient composition. The volatilization of the aroma therapy aroma oil is preferably promoted by heating an inorganic porous, zeolite or diatomite container, a metal-processing container, a wood-processing container, an earthenware-processing container, a plastic-processing container, or a container comprising their combination. The volatilization of the aromatic oil extracted from a plant having an aroma therapy aromatic property is promoted with the processing container. The volatilization of the aroma is mass produced in a large amount with a relatively simple device without needing a high cost installation investment.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The present invention demonstrates that epibatidine binds to nicotinic receptors on leukocytes. Epibatidine is a sensitive detector of increases in the number of nicotinic receptors expressed by a cell. Epibatidine binds to the leukocytes of smokers, but does not bind to the leukocytes of non-smokers. Both in vivo and ex vivo nicotine exposure induces epibatidine receptor expression. Epibatidine binding to leukocytes reflects epibatidine binding in the central nervous system, which in turn reflects nicotine-induced effects on the central nervous system. Epibatidine binding assays in peripheral blood leukocytes can be used to evaluate an individual&#39;s exposure to, and dependence on, nicotine.
The present invention relates to a medicinal artificial composition for replacing a natural snake bile, namely an artificial snake bile which is characterized in that the artificial snake bile is solution or a dry product containing sodium taurocholate and sodium deoxy taurocholate, and the substances of viper sodium tauroglycocholate, sodium tauroglycocholate, cholesterol, mucoprotein, zinc chloride, calcium chloride, magnesium chloride, cupric chloride dihydrate, chicken&#39;s gallbladder pigment, etc. can also be contained. The product can also be prepared by adding sodium taurocholate, sodium deoxy taurocholate, etc. to animal bile, such as detoxicated fish bile or treated chicken&#39;s bile, etc. Animal experiments prove that the artificial snake bile of the present invention has the obvious effect of relieving cough, eliminating phlegm, relieving asthma, etc. The efficiency is equivalent to or even better than that of a natural snake bile, and the toxicity is no more than that of the natural snake bile.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to pharmaceutical industry, biotechnology and medicine, particularly to methods of producer cell destruction, and can be used in insulin substances production. A commercial production process of human recombinant insulin involves the bacterial cell destruction; the bacterial cell destruction and following filtration are performed in a nanohomogeniser. The nanohomogeniser &#39;Microfluidiser&#39; is used as said nanohomogeniser. The bacterial cell destruction is performed at pressure 2070 bar and flow rate 330-450 ml/min. ^ EFFECT: use of the method provides higher efficiency and reduced length of the technological commercial insulin production process; the recombinant protein granule yield is 98%, the one-stage cell destruction is enabled, the granules of the same nanosize, particularly 60-80 nm are produced. ^ 1 dwg, 1 tbl, 1 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a textile material having a sufficient amount of minus ion generated and to provide a method for producing the same.  &lt;P&gt;SOLUTION: (1) The textile material comprises a minus ion generating body which is stuck fast through a positively charging binder resin to at least one side of a fabric. (2) The textile material comprises the minus ion generating body which is stuck fast through a binder resin to at least one side of a fabric having an antistatic layer. (3) The textile material comprises the minus ion generating body stuck fast through the binder resin to at least one side of the fabric in which the thickness of a binder resin layer containing the binder resin is ≥1 μm. (4) The textile material comprises the minus ion generating body stuck fast through the positively charging binder resin to at least one side of the fabric having the antistatic layer. (5) Minus ion having beneficial effect on the human body is surely generated by the textile material comprising a slit yarn obtained by slitting the above-mentioned textile material.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The present invention relates to a traditional Chinese medicine resisting oxidation and delaying senescence and a preparation method thereof. The traditional Chinese medicine is prepared from the following components in portions by weight: 3 to 12 portions of red ganoderma extract, 3 to 12 portions of grape seed extract, 2 to 8 portions of yam extract, and 2 to 8 portions of natural carotene. The extracts are obtained by extraction and filtration with the technological processes of cleaning and selecting, impurity removal, boiling with water or heating with etanol for reflux or fermentation cultivation, etc. The medicine has the advantages of stable quality, exact efficiency and high safety. In an experiment for causing mouse subacute senility, the medicine can enhance a mouse&#39;s diving tower test accomplishment and memory, the mouse&#39;s spleen coefficient is obviously increased, and the medicine can raise the contents of the antioxidase SOD and GSH-Px in brain tissues, reduce the generation of the peroxide free radical and reduce the content of the MAO in the brain tissues. The medicine also has good effects of activating blood circulation, dissipating stasis and stabilizing cell membranes.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a filing system capable of making access to a desired document file 29 while storing and controlling a large number of document files 29, and realizing the weight reduction and free maintenance at low cost.  &lt;P&gt;SOLUTION: The filing system comprises document storage shelves 1(1)-1(N) which are relatively moved by the drive of a control mechanism 3 with one of them being selectively moved to the entry/delivery position, a platform 2 for entry/delivery arranged at the entry/delivery position, and a control unit 4. Each of the document storage shelves 1(1)-1(N) is divided into a plurality of divisions 9 by a plurality of partitions 8. The document file 29 having an ID tag 30 is stored in each division 9, and the platform 2 for entry/delivery has a plurality of guide divisions 11 divided by guide plates 10 of the same number as that of the plurality of partitions 8, and a plurality of sensors 12 and an indicator 13 arranged for each guide division 11. The control unit has a controller 18, the document storage information database 19, and various interfaces 20-24.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A health care system is provided for analyzing a user&#39;s health on the basis of a large amount of health information and informing him or her of the danger of life style (related) disease. The system includes a health care center terminal connected via a network to a user terminal. The system also includes an analytic server connected to the health care center terminal. The health care center terminal has a diagnostic form display function for displaying on the user terminal a diagnostic form, in which the user can enter predetermined health information. The health care center terminal also has a health information reception function for receiving the information entered in the diagnostic form. The health care center terminal further has a health information transmission function for transmitting the received information to the analytic server. The analytic server has a health information database. The analytic server also has a health analysis function for receiving the transmitted information, and analyzing the user&#39;s health on the basis of the received information and the database. The analytic server further has an analyzed information transmission function for transmitting via the health care center terminal to the user terminal the information analyzed by the server.
PURPOSE:To obtain the title preventive and treating agent, containing live or dead microbial cells of Clostridium sp. strain NIP1201 or a cultivation filtrate thereof as an active ingredient, having high safety and capable of exhibiting excellent effects. CONSTITUTION:A preventive and treating agent containing live or dead microbial cells of Clostridium sp. strain NIP1201 (FERM P-9570) which is a Gram-positive, strict anaerobic and sporulating bacillus or a cultivation filtrate thereof as an active ingredient. The above-mentioned live microbial cells are capable of propagating in the digestive tracts after administration and intracellularly or extracellulary producing the active ingredient. The active ingredient is also contained in the cultivation filtrate obtained by cultivating the microorganism or dead microbial cells. The afore-mentioned preventive and treating agent is orally administered and the dose thereof is within the range of 10&lt;6&gt;-10&lt;10&gt; cells expressed in terms of viable cell number per kg body weight.
PURPOSE:To prepare an active fraction for lowering cholesterol level, useful as an orally administrable non-toxic antiarteriosclerotic agent and its raw material, by culturing bacterial strain of Streptococcus genus, extracting the bacterial cell with water, and separating a fraction having a specific molecular weight from the extract. CONSTITUTION:Bacterial strain belonging to Streptococcus genus (e.g. Streptococcus faecium, Streptococcus faecalis, Streptococcus bovis, etc.) is cultured e.g. aerobically in a liquid medium, and the cultured product is centrifuged to separate the bacterial cells. The cells are extracted with water, and dialyzed with a dialyzing membrane having a cut-off molecular weight of 3,500 (Cellotube; product of Nakarai Chemical Co.) to collect the fraction containing the components having molecular weight of &gt;=3,500 and active to lower the cholesterol level. The fraction is an orally administrable non-toxic material which lowers the cholesterol level in blood, effectively. It is effective to arteriosclerosis, hyperlipemia, hyperlipoproteinemia, etc.
One of the primary focuses of newer potential cancer treatment discovery is maximized efficacy with minimal side effects. The extent to which many standard of care cancer-fighting treatments can be administered to a patient is limited by the side effects, which are often lethal with extended dosing.  As such, researchers are looking more toward naturally occurring molecules and treatments with minimal or no side effects. Tocotrienols, a naturally occurring molecule found in red palm and other plants, have been studied extensively due to their anti-cancer properties. Dichloroacetate has also been more recently studied for it&#39;s cancer-fighting properties and presents an opportunity for synergistic efficacy when coupled with tocotrienol, both by formulation and by chemical linking. With synergistic combinations of potential treatments, newer treatment mechanisms can be achieved with higher efficacy and a resulting minimization or complete lack of side effects.
NEW MATERIAL:A compound expressed by the formula (n is O or 1). USE:A remedy and preventive for leukemia having human granulocyte colony stimulating factor activity. PREPARATION:For example, a solution of guanidinethiocyanate is added to a human tumorous cell and homogenized, then all PNA is separated by a CsCl density gradient centrifugation method and from this all PNA a poly (A&lt;+&gt;) PNA is screened with an origo (dT) cellulose column, a single stranded cDNA is synthesized by using a reverse transcriptase and converted into a double stranded DNA. Then thus obtained DNA is combined with a proper vector to form a recombinant plasmid, which is inserted into Escherichia coli, etc., to cause transformation thereof. This transformed Escherichia coli is cultured. The compound expressed by the formula is obtained by separating a product from the culture liquid.
The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions. The midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons made using the methods of the present invention are further contemplated for various uses including, but not limited to, use in in vitro drug discovery assays, neurology research, and as a therapeutic to reverse disease of, or damage to, a lack of dopamine neurons in a patient. Further, compositions and methods are provided for differentiating midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons from human pluripotent stem cells for use in disease modeling, in particular Parkinson&#39;s disease. Additionally, authentic DA neurons are enriched for markers, such as CD 142, and A9 type neuronal cells. 10612438_1 (GHMatters) P96995.AU.1
An unbiased ETL (extract, transform, load) system for timed medical event prediction utilizes a rolling series of time-bound cross-sections of patient healthcare data. Patients may be labelled as belonging to one or more classes (e.g. positive or negative) for each cross-section in the series depending on current healthcare status. Rather than using a single snapshot, the unbiased ETL system employs multiple snapshots of patient medical histories to provide a capability to classify a patient at different points in time, as appropriate. Supervised learning for the system is thereby enabled over multiple different periods of a patient&#39;s medical journey which advantageously supports a more statistically robust medical event prediction model and eliminates several classes of bias. Additionally, the unbiased ETL system enables customization of a prediction window to account for lags in data collection, data processing, and length of use of the medical event predictions.
Transplant of donor perfectly matched HLA hematopoietic stem cell to cure Sickle cell anemia and other anemia such as leukemia. Sterilized In vivo transplantation of clinically adequate quantities of antibiotic protected HLA vector/or insertion corrected chimera stem cells, and switching protein. Stem cells can be transfected for Hbg SS, and other proteins such as minor HLA type that may cause Graft versus host disease (GvHD) or Host versus Graft disease (HvGD Universal donor blood, Rh-negative of any HLA type can be corrected to perfectly match that of any recipient. Batch universal stem calls are grown and selectively transformed to a chimera stem cell. The chimera stem cells are incubated in a bio-reactor in growth medium also containing human growth and maturation promotion polypeptide factors. The harvest is then prepared for clinical use and transplantation into the matching recipient. Recipient&#39;s stem cells are transformed by transfection or insertion of the beta hemoglobin gene.
FIELD: organic chemistry, chemical technology, medicine, pharmacy. SUBSTANCE: invention relates to tricyclic condensed heterocyclic compounds of the formula (I)   wherein X means, for example, CH, CH 2 , CHR (wherein R means lower alkyl group or substituted lower alkyl group) or CRR&#39; (wherein R and R&#39; have values indicated above for R); Y means, for example, CH, CH 2  or C=O; z means, for example, sulfur atom, S=O; U means carbon atom, R 1 -R 4  mean independently, for example, hydrogen atom, SR (wherein R has above mentioned values), phenyl group, substituted phenyl group, furyl group, thienyl group, benzofuryl or benzothienyl; at least one radical among R 5  and R 8  means hydroxyl group and other radicals R 5  and R 8  mean independently, for example, hydrogen atom. Invention relates also to their optical isomers, conjugates and pharmaceutically acceptable salts. Indicated compounds are characterized by broad spectrum of pharmacological effect, in part, they exhibit relaxing effect on trachea smooth muscles, inhibit allergic response of respiratory ways excellently, inhibit infiltration of inflammatory cells into respiratory ways and, except for, they are harmless. Invention describes also method for preparing compounds, a pharmaceutical composition based on thereof and intermediate compounds of the synthesis. EFFECT: improved preparing method, valuable medicinal properties of compounds. 21 cl, 20 tbl, 184 ex
The invention relates to a traditional Chinese medicine composition for treating stomach trouble, and a preparation method thereof. The traditional Chinese medicine composition can be used for treating atrophic gastritis, superficial gastritis, stomach ulcer and duodenal ulcer. Traditional Chinese medicine raw materials for preparing effective components of the traditional Chinese medicine composition comprise 10-200 parts by weight of bighead atractylodes rhizome, 10-100 parts by weight of chicken&#39;s gizzard membrane, 10-200 parts by weight of poria cocos, 10-150 parts by weight of fig, 10-200 parts by weight of roasted malt, 10-100 parts by weight of dried tangerine or orange peel, 10-150 parts by weight of motherwort, 1-50 parts by weight of almonds and 10-150 parts by weight of pawpaw. The invention also provides the preparation method of the traditional Chinese medicine composition. The above traditional Chinese medicine raw materials are made into various common preparations which are convenient for being taken by people. The traditional Chinese medicine composition is reasonable in formula, is highly targeted, has significant curative effects of treating digestive diseases such as atrophic gastritis, superficial gastritis, stomach ulcer and duodenal ulcer, and has no toxic or side effect.
NEW MATERIAL:A monoclonal antibody reacting specifically with both human Epidermal Growth Factor (h-EGF for short) and mouse Epidermal Growth Factor (m-EGF for short), produced by using a highly purified h-EGF as an antigen. USE:For purifying h-EGF or m-EGF or for detecting biochemical or clinical h-EGF or m-EGF, etc. Easily producible at low cost. PREPARATION:Firstly, an animal such as mouse, etc., is immunized against highly purified h-EGF having preferably &gt;=99% purity as an antigen, the splenocyte of the animal is extracted to prepare an antibody-forming cell. Then, the splenocyte is fused with a tumor cell to give a hybridoma and a hybridoma producing a desired antibody is selected. Finally, the hybridoma, for example, is cultivated in a growth medium and the aimed antibody is collected from the culture supernatant liquid according to a conventional procedure.
The present invention relates to a novel human gene which has been shown to induce differentiation of cancer cells. The gene is regulated by NO and is named rno. Three isoforms of rno have been isolated and purified, rno-1 (SEQ ID NO: 1), rno-2 (SEQ ID NO: 3), and rno-3 (SEQ ID NO: 5). The rno isoforms each code for a separate amino acid sequence (SEQ ID NOS: 2, 4, &amp; 5 ). The present invention also provides recombinant vectors comprising nucleic acid molecules that code for the rno gene products. In certain embodiments, these recombinant vectors are plasmids. In certain embodiments, these recombinant vectors are prokaryotic or eukaryotic expression vectors. In certain especially preferred embodiments, the nucleic acid coding for the rno gene products are operably linked to a heterologous promoter. The present invention further provides host cells comprising a nucleic acid that codes for the rno gene products (SEQ ID NOS: 2, 4, &amp; 5). The gene products have been shown to induce AML cell differentiation and apoptosis.
552,286. Hair waving &amp;c. CHAMBERLAIN, N. H. July 24, 1941, No. 9368. Divided out of 552,285. [Class 15 (ii)] [Also in Group VIII] In a process for applying a permanent form or set to, or removing stress from, material made of keratin, the material is treated with an acid solution of a reducing agent, preferably a bisulphite or metabisulphite with or without alcohol, and then treated with a non-irritant alkaline solution containing an organic base or a non-irritant alkaline buffered solution. A suitable solution of an organic base consists of commercial triethanolamine and water to which may be added the sodium salt of isopropyl naphthalene sulphonic acid or other wetting agent, the preferred pH being 9 to 13. The general treatment of the hair in hair waving is as described in Specification 552,285. A suitable buffered solution with a pH of about 11 may be made by mixing a solution of disodium hydrogen phosphate with a solution of sodium hydroxide. Specification 453,700 also is referred to.
PROBLEM TO BE SOLVED: To obtain a new compound useful as a raw material for antifungal agents which are therapeutic agents for athlete&#39;s foot. SOLUTION: This N-benzylbenzamide derivative is represented by the formula [R1, R2, R3, R4, R5, R6, R7 or R8 are each independently H, a 1-4C alkyl, etc.], e.g. N-methyl-N-(2-phenylbenzyl)-4-tertiary-butylbenzoic acid amid. The compound of the formula is obtained by reacting an N-methylbenzylamine derivative obtained from a benzoic acid derivative with a halide in the presence of a base such as (C2 H5 )3 N. The resultant compound can be purified by ordinary means such as silica gel column chromatography or recrystallizatino. Furthermore, the compound of the formula is reacted with a reducing agent in a solvent such as ether to provide an antifungal agent.
PURPOSE:To obtain a new compound useful treating gynecological disease, osteoporosis, prostatic carcinoma, prostatic hypertrophy, etc. CONSTITUTION:A compound shown by the formula. The compound is obtained by culturing a fungus belonging to the genus Scedosporium apiospermum or a variant thereof, fungus F26,263 strain in a nutrient-containing medium under an aerobic condition. Physical and chemical properties BE-26,263. White amorphous solid or crystal. Molecular formula: C38H38O14. Specific rotatory power: [alpha]D&lt;20&gt;=-24.3 deg. (C=0.983, methanol). Solubility: soluble in methanol, ethanol, acetone, ethyl acetate and chloroform and insoluble in water and n-hexane. Acidity. Color reaction: positive in potassium permanganate reaction. Strongly antagonizing bond of estrodiol acceptor, showing antagonist activity but not antagonizing bond of progesterone acceptor.